<DOC>
	<DOC>NCT02419417</DOC>
	<brief_summary>The purpose of this study is to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of BMS-986158 in subjects with select advanced solid tumors.</brief_summary>
	<brief_title>Study of BMS-986158 in Subjects With Select Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Must have triple negative breast cancer, ovarian (Serous histology for expansion phase), small cell lung cancer, or other solid tumors Expected to have life expectancy of at least 3 months Men and women 18 years old or older At least one measurable lesion at baseline by CT or MRI as per response evaluation criteria in solid tumors (RECIST) v1.1 Eastern Cooperative Oncology Group (ECOG) of 0 to 1 Serious or uncontrolled medical disorders Concomitant second malignancies Uncontrolled or significant cardiovascular disease Inadequate bone marrow function Other protocol defined inclusion/exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>